The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CADL | +8.78% | N/A | N/A | -24% |
| S&P | +13.09% | +85.73% | +13.17% | +56% |
Candel Therapeutics, Inc. is a late clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.20M | 20.4% |
| Market Cap | $279.97M | 25.9% |
| Market Cap / Employee | $7.37M | 0.0% |
| Employees | 38 | -9.5% |
| Net Income | -$11.27M | -5.9% |
| EBITDA | -$13.01M | -52.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $86.96M | 425.2% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.55M | -54.7% |
| Short Term Debt | $4.66M | -55.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -39.54% | 106.3% |
| Return On Invested Capital | -75.13% | -11.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$10.38M | -57.9% |
| Operating Free Cash Flow | -$10.24M | -55.7% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -18.28 | 4.00 | 3.34 | 3.10 | -114.37% |
| Price to Tangible Book Value | -18.28 | 4.00 | 3.34 | 3.10 | -114.37% |
| Enterprise Value to EBITDA | -27.80 | -28.94 | -15.38 | -15.39 | -40.82% |
| Return on Equity | -139.6% | -98.1% | -55.2% | -70.2% | -94.78% |
| Total Debt | $13.47M | $10.91M | $8.34M | $7.21M | -55.02% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
